Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.

about

Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.

P2860

Q40047199-48CEB302-3F5A-4A29-868B-91DE42D96BA2

P2860

Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.

Item

http://www.wikidata.org/entity/Q39046213

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Drug-induced progressive multi ...... opean regulators' perspective.

@en

Drug-induced progressive multi ...... opean regulators' perspective.

@nl

type

Item

label

Drug-induced progressive multi ...... opean regulators' perspective.

@en

Drug-induced progressive multi ...... opean regulators' perspective.

@nl

prefLabel

Drug-induced progressive multi ...... opean regulators' perspective.

@en

Drug-induced progressive multi ...... opean regulators' perspective.

@nl

P1476

Drug-induced progressive multi ...... opean regulators' perspective.

@en

P2093

B Keller-Stanislawski

http://www.w3.org/2001/XMLSchema#string

G Mazzaglia

http://www.w3.org/2001/XMLSchema#string

J Raine

http://www.w3.org/2001/XMLSchema#string

L Prieto

http://www.w3.org/2001/XMLSchema#string

M Haas

http://www.w3.org/2001/XMLSchema#string

M Weise

http://www.w3.org/2001/XMLSchema#string

P Arlett

http://www.w3.org/2001/XMLSchema#string

P Balabanov

http://www.w3.org/2001/XMLSchema#string

R Anton

http://www.w3.org/2001/XMLSchema#string

P2860

Progressive multifocal leukoencephalopathy: current treatment options and future perspectives

JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?

Structure-Function Analysis of the Human JC Polyomavirus Establishes the LSTc Pentasaccharide as a Functional Receptor Motif

Is there a (host) genetic predisposition to progressive multifocal leukoencephalopathy?

Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors

Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls

Pooling real-world multiple sclerosis patient data on a European level: a true story of success.

A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together

Viral miRNAs in plasma and urine divulge JC polyomavirus infection.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

P304

283-289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPT.604

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28001298

http://www.w3.org/2001/XMLSchema#string

P921

progressive multifocal leukoencephalopathy

multiple sclerosis

Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.

about

P2860

P2860

Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921